Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gin Hwa BiotechROCO:7806 22 Buyback Yield % is -14.37 as of Jul. 22, 2026. GuruFocus rates ROCO:7806 with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 740 Biotechnology companies, Gin Hwa Biotech ranks worse than 60.14% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Gin Hwa Biotech's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7806 vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Gin Hwa Biotech's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gin Hwa Biotech Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gin Hwa Biotech's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Gin Hwa Biotech's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gin Hwa Biotech (ROCO:7806) has a Buyback Yield % of -14.37 as of Jul. 22, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Gin Hwa Biotech and its competitors. According to the industry distribution chart, Gin Hwa Biotech ranks #445 out of 740 companies in the Biotechnology industry, placing it in the top 60.1%.
Is Gin Hwa Biotech's Buyback Yield % too high?
Gin Hwa Biotech's current Buyback Yield % is -14.37. Based on the distribution chart, Gin Hwa Biotech ranks #445 out of 740 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Gin Hwa Biotech has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Gin Hwa Biotech's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gin Hwa Biotech ranks #445 out of 740 companies for Buyback Yield %. This places Gin Hwa Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Gin Hwa Biotech and its competitors. Gin Hwa Biotech's current Buyback Yield % is -14.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gin Hwa Biotech stock overvalued right now?
Gin Hwa Biotech (ROCO:7806) has a current Buyback Yield % of -14.37. The current Buyback Yield % is -14.37. Gin Hwa Biotech's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Gin Hwa Biotech (ROCO:7806), the current Buyback Yield % is -14.37 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gin Hwa Biotech Inc is engaged in developing completely original products to achieve every vision. Its Services and technology are Product Development, OEM Service, Core Technology, R & D Center, Professional Production, and Others.
22GF Score
Get the complete analysis for ROCO:7806
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7806 has been successfully added to your 
